Vulvær intraepithelial neoplasi

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelFormidling

Standard

Vulvær intraepithelial neoplasi. / Hansen, Signe Østergaard; Vorbeck, Christina Steen; Meinert, Mette.

I: Ugeskrift for Laeger, Bind 2018, Nr. 180, V2170931, 01.05.2018, s. 2-5.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelFormidling

Harvard

Hansen, SØ, Vorbeck, CS & Meinert, M 2018, 'Vulvær intraepithelial neoplasi', Ugeskrift for Laeger, bind 2018, nr. 180, V2170931, s. 2-5.

APA

Hansen, S. Ø., Vorbeck, C. S., & Meinert, M. (2018). Vulvær intraepithelial neoplasi. Ugeskrift for Laeger, 2018(180), 2-5. [V2170931].

CBE

Hansen SØ, Vorbeck CS, Meinert M. 2018. Vulvær intraepithelial neoplasi. Ugeskrift for Laeger. 2018(180):2-5.

MLA

Hansen, Signe Østergaard, Christina Steen Vorbeck, og Mette Meinert. "Vulvær intraepithelial neoplasi". Ugeskrift for Laeger. 2018, 2018(180). 2-5.

Vancouver

Hansen SØ, Vorbeck CS, Meinert M. Vulvær intraepithelial neoplasi. Ugeskrift for Laeger. 2018 maj 1;2018(180):2-5. V2170931.

Author

Hansen, Signe Østergaard ; Vorbeck, Christina Steen ; Meinert, Mette. / Vulvær intraepithelial neoplasi. I: Ugeskrift for Laeger. 2018 ; Bind 2018, Nr. 180. s. 2-5.

Bibtex

@article{86fe6642a2da4d13bbe7b444ce36452a,
title = "Vulv{\ae}r intraepithelial neoplasi",
abstract = "Vulvar intraepithelial neoplasiaVulvar intraepithelial neoplasia (VIN) is a rare but premalig­nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.",
keywords = "Vulvar Neoplasms, imiquimod, vulva dysplasi imiquimod",
author = "Hansen, {Signe {\O}stergaard} and Vorbeck, {Christina Steen} and Mette Meinert",
year = "2018",
month = may,
day = "1",
language = "Dansk",
volume = "2018",
pages = "2--5",
journal = "Ugeskrift for L{\ae}ger ",
issn = "0041-5782",
publisher = "Den Almindelige Danske L{\ae}geforening",
number = "180",

}

RIS

TY - JOUR

T1 - Vulvær intraepithelial neoplasi

AU - Hansen, Signe Østergaard

AU - Vorbeck, Christina Steen

AU - Meinert, Mette

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Vulvar intraepithelial neoplasiaVulvar intraepithelial neoplasia (VIN) is a rare but premalig­nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.

AB - Vulvar intraepithelial neoplasiaVulvar intraepithelial neoplasia (VIN) is a rare but premalig­nant condition. VIN has two aetiological pathways: a human papillomavirus (HPV)-dependent pathway, which is a vulvar high-grade squamous intraepithelial lesion (HSIL), and an HPV-independent pathway, called differentiated VIN (d-VIN), associated with lichen sclerosus. d-VIN is more aggressive than vulvar HSIL. In case of symptoms, a biopsy should be performed. The recurrence risk is high: 25-50% regardless of treatment type. We recommend treatment with imiquimod as first choice to avoid mutilating surgery. Particular attention must be payed to immunosuppressed patients with VIN. HPV-vaccine can be discussed with patients with vulvar HSIL.

KW - Vulvar Neoplasms

KW - imiquimod

KW - vulva dysplasi imiquimod

M3 - Tidsskriftartikel

VL - 2018

SP - 2

EP - 5

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

SN - 0041-5782

IS - 180

M1 - V2170931

ER -